Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial von Lannfelt, Lars, MD, Blennow, Kaj, MD, Zetterberg, Henrik, MD, Batsman, Stellan, MD, Ames, David, MD, Harrison, John, PhD, Masters, Colin L, MD, Targum, Steve, MD, Bush, Ashley I, MBBS, Murdoch, Ross, PhD, Wilson, Janet, RN, Ritchie, Craig W, MBChB

Volltext

Deep brain stimulation targeting the fornix for mild Alzheimer dementia: design of the ADvance randomized controlled trial von Holroyd, Kathryn B, Fosdick, Lisa, Smith, Gwenn S, Leoutsakos, Jeannie-Marie, Munro, Cynthia A, Oh, Esther S, Drake, Kristen E, Rosenberg, Paul B, Anderson, William S, Salloway, Stephen, Pendergrass, J.Cara, Burke, Anna D, Wolk, David A, Tang-Wai, David F, Ponce, Francisco A, Asaad, Wael F, Sabbagh, Marwan N, Okun, Michael S, Baltuch, Gordon, Foote, Kelly D, Targum, Steven D, Lozano, Andres M, Lyketsos, Constantine G

Volltext

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial von Lannfelt, Lars, Blennow, Kaj, Zetterberg, Henrik, Batsman, Stellan, Ames, David, Harrison, John, Masters, Colin L, Targum, Steve, Bush, Ashley I, Murdoch, Ross, Wilson, Janet, Ritchie, Craig W

Volltext

Safety, efficacy, and biomarker findings of PBT2 in targeting A[beta] as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled tria... von Lannfelt, Lars, Blennow, Kaj, Zetterberg, Henrik, Batsman, Stellan, Ames, David, Harrison, John, Masters, Colin L, Targum, Steve, Bush, Ashley I, Murdoch, Ross, Wilson, Janet, Ritchie, Craig W

Volltext